Document is current

Article History

Accepted: 1 September 2024

First Online: 5 October 2024

Declarations

:

: This study was supported by the sponsor, Zai Lab (Shanghai) Co., Ltd.

: A.G., a former argenx employee, is a consultant to argenx currently. J.N. and T.V.B. are consultants to argenx. X.G., J.L., L.W., J.C., H.R., and X.P. are employees of Zai Lab, and they hold stock options and shares in Zai Lab. The other authors have no relevant financial or nonfinancial interests to disclose.

: Both studies were conducted in accordance with the Good Clinical Practice of the International Conference for Harmonisation guidelines, applicable local regulatory requirements, and the principles of the Declaration of Helsinki. IV study, approval number 2021-17, approval date 7 June 2021; SC study, approval number 2021-0236-02, approval date 29 June 21.

: All study participants provided written informed consent prior to the study.

: All authors approved the manuscript for publication.

: Please contact Zai Lab (Shanghai) Co., Ltd., for data inquiries.

: Not applicable.

: All authors equally contributed to the study conception, data visualization, review and editing of the manuscript, analysis of the data, conduct of research investigations, development of methods, and administration of projects.